ReviewNature reviews. Rheumatology2021
Current and future therapies for primary Sjögren syndrome.
Review in Nature reviews. Rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Network meta-analysis of integrated traditional Chinese and Western medicine in the treatment of Sjogren's syndrome.Frontiers in pharmacology · 2024Pooled it
- Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.Annals of the rheumatic diseases · 2022Pooled it
- Serum exosomal tRNA-derived small RNAs as diagnostic biomarkers for primary Sjögren's syndrome: a combined model with autoantibodies.Clinical rheumatology · 2026Article
- From Molecular Pathophysiology to Clinical Trial Design in Sjögren's Disease: A Three-Axis Framework.International journal of molecular sciences · 2026Review
- Low-to-moderate dose glucocorticoids in primary Sjögren's syndrome patients on hydroxychloroquine/iguratimod therapy: a target trial emulation study.Clinical rheumatology · 2026Article
- CCR1Journal of advanced research · 2026Article
- Interferon signaling gene expression, and DNA methylation interactions in Sjögren's disease via mendelian randomization.iScience · 2026Article
- Risk factors for disease progression in primary Sjögren's syndrome patients with low disease activity: a multicenter registry-based cohort study.Clinical rheumatology · 2026Article
- An Ultrasound-Based Machine Learning Model for Differentiating IgG4-Related Sialadenitis and Primary Sjögren's Syndrome.International dental journal · 2026Article
- Identification and validation of necroptosis-related genes in peripheral blood mononuclear cells of Sjögren disease.Frontiers in medicine · 2026Article
- Deciphering the interferon gene signature spectrum: association with the clinical heterogeneity of Sjögren's disease.Frontiers in immunology · 2026Article
- Nanotechnology-Based Modulation of Autoimmune Microenvironments in Sjögren's Syndrome: A Review of Mechanistic Perspectives.International journal of nanomedicine · 2026Review
- Spatiotemporal orchestration of the salivary gland immune microenvironment in Sjögren's disease: a multidimensional framework of epithelial licensing, lymphoid neogenesis, and stromal remodeling.Frontiers in immunology · 2026Review
- Tracheobronchial amyloidosis in a 64-year-old woman with type 2 diabetes mellitus and Sjögren's syndrome: a case report.American journal of translational research · 2026Article
- Mesenchymal stem cells ameliorate Sjögren disease by suppressing B cells through the Pik3cb/Akt/mTOR pathway.Frontiers in immunology · 2026Article
- From endotypes to therapeutic targets: exploring the potential of precision treat-to-target approaches in primary Sjögren's disease.Clinical rheumatology · 2025Review
- Comparative outcomes of COVID-19 in patients with primary Sjögren's syndrome treated with hydroxychloroquine versus methotrexate: a retrospective cohort study.Annals of medicine · 2025Article
- CD8+ T cell depletion promotes human Tph/Tfh cell proliferation and Sjögren syndrome-like symptoms in PBMC-based humanized mice.JCI insight · 2025Article
- The STING/type I interferon axis drives the interplay between marginal zone B cells and T follicular helper cells in Sjögren's disease.Cellular & molecular immunology · 2025Article
- Regulatory Role of FGL-1 in Interorgan Communication by Controlling T Cell Homeostasis During the Onset of Sjögren Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that is characterized by a triad of symptoms that affect all patients (dryness, pain and fatigue). In addition, systemic involvement can affect between one-third and one-half of patients. The management of patients with pSS has been negatively affected by a lack of effective treatments; however, knowledge of the epidemiology of pSS has increased, and advances in developing classification criteria, systemic disease activity scoring and patient-reported outcomes have been made during the past decade. Progress has also been made in understanding the mechanisms that underlie the pathogenesis of pSS, which has enabled a more targeted therapeutic approach to be taken. At present, therapeutic decisions rely on the evaluation of symptoms and systemic manifestations and are mostly formed on the basis of experience rather than evidence, and on similarities with other autoimmune diseases, although the 2019 management recommendations from EULAR are now being used to inform clinical management of pSS. This Review summarizes the available evidence for systemic treatments for pSS and includes discussions of advances in outcome assessment, the current evidence for DMARD use and an overview of promising future therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.